Mesoblast
MESO

Mesoblast (MESO) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
Piper SandlerMaintainedOverweight$39.00 from $35.00Aug 27, 2026
JefferiesUpgradedHold → BuyNov 25, 2025
JefferiesDowngradedBuy → HoldJul 18, 2025
Piper SandlerMaintainedOverweight$24.00 from $15.00Feb 7, 2025
JefferiesDowngradedBuy → HoldDec 23, 2024
Piper SandlerMaintainedOverweight$15.00 from $11.00Dec 19, 2024
Maxim GroupUpgradedHold → Buy$12.00Sep 24, 2024
JefferiesUpgradedHold → BuyAug 29, 2024
Cantor FitzgeraldMaintainedOverweightAug 29, 2024
Piper SandlerUpgradedNeutral → Overweight$11.00 from $4.00Jul 23, 2024
Cantor FitzgeraldMaintainedOverweightJun 20, 2024
Cantor FitzgeraldMaintainedOverweightJun 4, 2024
Cantor FitzgeraldMaintainedOverweight$17.00Sep 21, 2023
Cantor FitzgeraldMaintainedOverweight$17.00 from $23.00Aug 31, 2023
JefferiesUpgradedHold → BuyAug 31, 2023
Maxim GroupDowngradedBuy → HoldAug 7, 2023
William BlairDowngradedOutperform → Market PerformAug 4, 2023
Chardan CapitalMaintainedSell$1.50 from $2.00Aug 4, 2023
Piper SandlerDowngradedOverweight → Neutral$2.00 from $7.00Aug 4, 2023
Chardan CapitalMaintainedSell$2.00 from $2.50May 30, 2023

Frequently asked questions

  • What is the latest analyst rating on MESO?

    On Aug 27, 2026, Piper Sandler maintained Mesoblast at Overweight with a price target of $39.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.